Science and Research

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) (SOTERIA), An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept in participants with Pulmonary Arterial Hypertension. The primary objective of this open-label, long-term follow-up study is to evaluate the long-term safety and tolerability of sotatercept when added to background PAH therapy in adult participants with PAH who have completed prior sotatercept studies. The secondary objective is to evaluate continued efficacy in adult participants with PAH who have completed prior sotatercept studies.

Study details
Study-ID: NCT04796337, 2020-005061-13
DZL Disease Area: PH
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
DZL Participating Sites: BREATH, TLRC, UGMLC
Start Date: 02.12.2021
Completion Date: 31.12.2027
Status: Active / not recruiting
Link to Study


chevron-down